According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion ...

RAHWAY, N.J., February 24, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li ...

In both trials, DOR/ISL met the primary efficacy success criterion for non-inferiority to comparator antiretroviral therapies and primary safety objective RAHWAY, N.J., March 12, 2025--Merck ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday (March 5, 2025), citing ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...